Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2006-06-13
2006-06-13
Nolan, Patrick J. (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C514S002600, C536S023100
Reexamination Certificate
active
07060797
ABSTRACT:
The present invention provides novel isolated BFLP0169 polynucleotides and polypeptides encoded by the BFLP0169 polynucleotides. Also provided are the antibodies that immunospecifically bind to a BFLP0169 polypeptide or any derivative (including fusion derivative), variant, mutant or fragment of the BFLP0169 polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the BFLP0169 polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.
REFERENCES:
patent: 6313264 (2001-11-01), Caggiano et al.
patent: 2002/0197679 (2002-12-01), Tang et al.
patent: 2003/0049804 (2003-03-01), Pompejus et al.
patent: 2004/0258678 (2004-12-01), Bodary et al.
Metzier et al., Nature Structural Biol., 1997, 4:527-531.
Attwood, Science, 2000, 290:471-473.
Skolnick et al. Trends in Biotech., 2000, 18(1):34-39.
Whisstock et al., Quarterly reviews of Biophysics, 2003, 36:307-340.
Ngo et al., 1994, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-494.
International Appl. No. PCT/US2003/37339, International Search Report mailed Apr. 5, 2005, 3 pages.
International Appl. No. PCT/US2003/37317, International Search Report mailed Jan. 6, 2005, 6 pages.
Balowe, J.E. et al., New prospects for treatment of lupus nephritis,Semin. Nephrol., 20(1):32-39 (2000).
Davis, J.C. et al., Lupus nephritis,Current Opin. Rheumatol., 8(5):415-423 (1996).
Mercada,L. and Deray, G., Lupus nephritis, a review of the current pharmacological treatments,Expert Opin. Pharmacother., 5(11):2263-2277 (2004).
Rahman, Z.S.M., et al., A novel susceptibility locus on chromosome 2 in the (NE Zealand blaxk x New Zealand white) F1hubrid mouse model of systematic lupus erythematosus,J. Immunol., 168(6):3042-3049 (2002).
Tsao, B.P., Genetic susceptibility to lupus nephritis,Lupus, 7(9):585-590 (1998).
Drake, et al., “Genetic analysi of the NZB contribution to lupus-like autoimmune disease in (NZB x NZW) F1 mice,”Pro Natl. Acad. Sci. USA91:4062-66, 1994.
Guglielmotti et al., “Bindarit prolongs survival and reduces renal damage of NSB/W lupus mice,”Clin. Exp. Pheumatol.16:149, 1998.
Finck et al., “Interleukin 6 promotes murine lupus in NZB/NZW F1Mice,”The J. Clin. Inveest.94:585-591, 1994.
Yang et al., “Dietary conjugated linoleic acid protects against end stage disease of systemic lupus erythematosus in the NZB/W F1 mouse,”Immunopharmacol. Immunotoxical.22:433-49, 2000.
Mounts William Martin
O'Toole Margot
Shojaee Negin
Kim Yunsoo
Kirkpatrick & Lockhart Nicholson & Graham LLP
Nolan Patrick J.
Wyeth
LandOfFree
Composition and method for treating lupus nephritis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and method for treating lupus nephritis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method for treating lupus nephritis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3654259